证券代码：688310 证券简称：迈得医疗 公告编号：2026-010 迈得医疗工业设备股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1.本报告期初数与法定披露的上年年末数一致。 2.以上财务数据及指标以合并报表数据填列，但未经会计师事务所审计，具体数据以公司2025年年度报 告为准。 3.以上数据如有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 2025年公司实现营业收入44,741.90万元，与去年同期相比上升62.79%；实现营业利润5,969.89万元，利 润总额6,122.32万元，实现归属于母公司所有者的净利润6,525.99万元，实现归属于母公司所有者的扣除 非经常性损益的净利润5,329.23万元，与去年同期相比变动较大，实现扭亏为盈。 报告期末，公司总资产118,704.03万元，与去年同期相比上升12.69%；归属于母公司的所有者权益 86 ...

业绩快报公告中对经营业绩和财务状况情况的说明： 2025 年公司实现营业收入 44,741.90 万元，与去年同期相比上升 62.79%；实现营业利润 5,969.89 万 元，利润总额 6,122.32 万元，实现归属于母公司所有者的净利润 6,525.99 万元，实现归属于母公司所有 者的扣除非经常性损益的净利润5,329.23 万元，与去年同期相比变动较大，实现扭亏为盈。 证券之星消息，迈得医疗近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润盈利 0.653亿元，同比增长426.61%。 该股最近90天内无机构评级。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2025 年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障了产品有 效交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净化类和药 械组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态 势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智 ...

2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障了产品有效 交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净化类和药械 组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态 势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产品研发和 市场开拓，本期药械组合类智能装备收入实现较大增长。 迈得医疗(688310.SH)发布2025年度业绩快报，2025年公司实现营业收入4.47亿元，与去年同期相比上升 62.79%;实现归属于母公司所有者的净利润6525.99万元，实现归属于母公司所有者的扣除非经常性损益 的净利润5329.23万元，与去年同期相比变动较大，实现扭亏为盈。 ...

2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障了产品有效 交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净化类和药械 组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态 势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产品研发和 市场开拓，本期药械组合类智能装备收入实现较大增长。 智通财经APP讯，迈得医疗(688310.SH)发布2025年度业绩快报，2025年公司实现营业收入4.47亿元，与 去年同期相比上升62.79%;实现归属于母公司所有者的净利润6525.99万元，实现归属于母公司所有者的 扣除非经常性损益的净利润5329.23万元，与去年同期相比变动较大，实现扭亏为盈。 ...

迈得医疗公告称，2025年度公司实现营业收入44,741.90万元，同比上升62.79%；实现归属于母公司所 有者的净利润6,525.99万元，实现扭亏为盈。报告期末，公司总资产118,704.03万元，同比上升 12.69%；归属于母公司的所有者权益86,239.57万元，同比上升6.46%。业绩增长主要因公司统筹生产、 坚持创新，血液净化类和药械组合类智能装备业务发展良好，药械组合类智能装备收入大增。数据未经 审计，以年报为准。 ...

Core Viewpoint - The company, Maide Medical Industrial Equipment Co., Ltd., anticipates significant growth in revenue and profitability for the year 2025, marking a turnaround from previous losses [2][9]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately 447.50 million yuan for 2025, representing an increase of about 172.65 million yuan, or 62.81% year-on-year [2]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, indicating a turnaround from a loss in the previous year [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated at approximately 54.64 million yuan [3]. Group 2: Previous Year Performance - In the previous year, the total profit was reported at -29.23 million yuan [5]. - The net profit attributable to the parent company was -19.98 million yuan [6]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -26.28 million yuan [7]. - The basic earnings per share for the previous year were -0.12 yuan [8]. Group 3: Reasons for Performance Change - The anticipated revenue growth is attributed to the company's effective production planning and delivery, alongside a focus on technological innovation and process iteration [9]. - The blood purification and medical device combination equipment sectors are performing well, particularly due to strong demand for medical consumables in the end market [9]. - The company is concentrating on research and market development for new products in the medical device combination equipment sector, which is expected to drive significant revenue growth [9].

Core Viewpoint - The company, Maide Medical, has released its 2025 annual performance forecast, indicating significant revenue growth and a return to profitability, primarily driven by increased sales in smart medical equipment [1]. Group 1: Financial Performance - As of January 26, 2026, Maide Medical's stock closed at 16.26 yuan, down 1.57% from the previous trading day, with a total market capitalization of 2.703 billion yuan [1]. - The company expects to achieve approximately 447.50 million yuan in revenue for 2025, representing a year-on-year growth of 62.81% [1]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, marking a return to profitability [1]. - The net profit after deducting non-recurring gains and losses is estimated to be about 54.64 million yuan [1]. Group 2: Revenue Drivers - The significant growth in revenue is primarily attributed to a substantial increase in sales of smart medical equipment, particularly in the drug and device combination sector [1].

截至2026年1月26日收盘，迈得医疗(688310)报收于16.26元，下跌1.57%，换手率1.94%，成交量3.23万 手，成交额5225.49万元。 资金流向 迈得医疗工业设备股份有限公司2025年年度业绩预告 经财务部门初步测算，预计迈得医疗2025年年度实现营业收入44,749.77万元左右，同比增长62.81%； 归属于母公司所有者的净利润为6,652.13万元左右，实现扭亏为盈；扣除非经常性损益后的净利润为 5,463.95万元左右。业绩增长主要得益于营业收入大幅提升，尤其是药械组合类智能装备收入显著增 长。本期业绩预告未经注册会计师审计。 1月26日主力资金净流出115.69万元；游资资金净流出11.45万元；散户资金净流入127.14万元。 业绩披露要点 业绩预告 迈得医疗发布业绩预告，预计2025年全年营业收入4.47亿元。迈得医疗发布业绩预告，预计2025年全年 扣非后净利润盈利约5463.95万元。迈得医疗发布业绩预告，预计2025年全年归属净利润盈利约6652.13 万元。 公司公告汇总 当日关注点 交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

中证智能财讯迈得医疗（688310）1月26日晚间披露2025年度业绩预告，预计2025年归母净利润6652.13万元，上年同期亏损1998.12万元；扣非净利润预计 5463.95万元，上年同期亏损2628.09万元。以1月26日收盘价计算，迈得医疗目前市盈率（TTM）约为40.63倍，市净率（LF）约3.35倍，市销率（TTM）约 9.66倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 200 @ 20 100 300 50 47624 40919 To83 29877 32x43 29.54 224 0 -50 -100 -150 2022-06-30 2021-12-37 2021-06-30 ' 2020-12-37 2022-12-37 <3-12-37 3-06-30 2n. -○- 公司 -○- 行业均值 100 ହ 90 80 70 63 69 60 50 (8 40 30 2 20 15086 15 10 AR 0 2027-12-37 | 2022-72-37 1 2020-12-37 1 2021-06-30 ' 023-12-37 ...

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 66.52 million yuan, driven by substantial growth in overall operating revenue and successful product delivery [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately 66.52 million yuan for the year 2025 [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and drug-device combination intelligent equipment business is performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to shareholders for the same period was 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2] - In Q3 2025 alone, the company reported a main revenue of 83.64 million yuan, a significant year-on-year increase of 54.38% [2] - The net profit for Q3 2025 was 2.79 million yuan, showing a remarkable year-on-year increase of 224.07% [2] - The company reported a debt ratio of 29.86% and a gross profit margin of 40.19% [2]